J. Schueller

发表

A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.

W. Scheithauer, A. Farkouh, D. Ettlinger, 2010, Anticancer research.

Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.

E. Kallay, H. Cross, J. Schueller, 2007, Cancer research.

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study

J. Schueller, S. Binder, F. Zeiler, 2009, British Journal of Ophthalmology.

Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.

A. Farkouh, J. Schueller, M. Czejka, 2010, Anticancer research.

In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.

W. Wadsak, M. Mitterhauser, A. Farkouh, 2006, Anticancer Research.

Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen

W. Scheithauer, A. Farkouh, J. Schueller, 2011, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.

J. Schueller, M. Czejka, E. Ostermann, 2005, Anticancer research.

Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab

Mansoor M Ahmed, J. Schueller, M. Czejka, 2013 .

Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin®)

J. Schueller, M. Czejka, E. Ostermann, 2005, European Journal of Drug Metabolism and Pharmacokinetics.

Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

W. Scheithauer, R. Herrmann, J. Bernhard, 2005 .

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Stefano Iacobelli, Francis Lévi, Antoine Adenis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts)

W. Scheithauer, H. Burris, J. Douillard, 2004 .

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

T. Gruenberger, F. Wrba, D. Tamandl, 2010, The Lancet. Oncology.

Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.

J. Schueller, M. Czejka, R. Freitag, 2000, Anticancer research.

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

M. Lehnert, J. Schueller, H. Kupper, 1998, British Journal of Cancer.

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

Thomas Gruenberger, Dietmar Tamandl, W. Scheithauer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting

D. Khayat, J. Schueller, A. Fauser, 2000, Supportive Care in Cancer.

Clinical Significance of Pharmacokinetic Drug Interactions between Interferon-α and Antineoplastic Drugs

J. Schueller, M. Czejka, C. Pietrzak, 1999, BioDrugs.

K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study.

T. Gruenberger, D. Tamandl, K. Kaczirek, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3064 POSTER Neoadjuvant bevacizumab plus XELOX is feasible in patients with potentially curable metastatic colorectal cancer receiving synchronous resection

W. Scheithauer, T. Gruenberger, D. Tamandl, 2007 .

Pharmacokinetics of Gemcitabine Combined with Trastuzumab in Patients with Advanced Breast Cancer

J. Schueller, M. Czejka, E. Ostermann, 2005, Oncology Research and Treatment.

Efficacy results of cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with advanced or metastatic cholangiocarcinoma: A single centre phase II study

T. Gruenberger, M. Bischof, K. Kaczirek, 2008 .

Differential diagnosis of benign and malign pancreatic masses with 18F-fluordeoxyglucose-positron emission tomography recorded with a dual-head coincidence gamma camera

J. Schueller, M. Gschwantler, H. Feichtinger, 2007, European journal of gastroenterology & hepatology.

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).

W. Scheithauer, H. Burris, J. Douillard, 2004, Journal of Clinical Oncology.

Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.

W. Scheithauer, A. Farkouh, J. Schueller, 2010, International journal of clinical pharmacology and therapeutics.

Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.

D. Ettlinger, J. Schueller, M. Czejka, 2011, Anticancer research.

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

S. Iacobelli, T. Gorlia, F. Lévi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.

W. Scheithauer, A. Farkouh, J. Schueller, 2014, Anticancer research.